1
|
del Campo-Balguerías A, Parra-Cadenas B, Nieto-Jimenez C, Bravo I, Ripoll C, Poyatos-Racionero E, Gancarski P, Carrillo-Hermosilla F, Alonso-Moreno C, Ocaña A. Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents. Int J Mol Sci 2023; 24:13820. [PMID: 37762123 PMCID: PMC10530677 DOI: 10.3390/ijms241813820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 08/29/2023] [Accepted: 09/03/2023] [Indexed: 09/29/2023] Open
Abstract
The modular synthesis of the guanidine core by guanylation reactions using commercially available ZnEt2 as a catalyst has been exploited as a tool for the rapid development of antitumoral guanidine candidates. Therefore, a series of phenyl-guanidines were straightforwardly obtained in very high yields. From the in vitro assessment of the antitumoral activity of such structurally diverse guanidines, the guanidine termed ACB3 has been identified as the lead compound of the series. Several biological assays, an estimation of AMDE values, and an uptake study using Fluorescence Lifetime Imaging Microscopy were conducted to gain insight into the mechanism of action. Cell death apoptosis, induction of cell cycle arrest, and reduction in cell adhesion and colony formation have been demonstrated for the lead compound in the series. In this work, and as a proof of concept, we discuss the potential of the catalytic guanylation reactions for high-throughput testing and the rational design of guanidine-based cancer therapeutic agents.
Collapse
Affiliation(s)
- Almudena del Campo-Balguerías
- Unidad nanoDrug, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain; (A.d.C.-B.); (I.B.); (C.R.)
- Departamento Química Inorgánica, Orgánica y Bioquímica, Facultad de Farmacia de Albacete-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Blanca Parra-Cadenas
- Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain; (B.P.-C.); (F.C.-H.)
| | - Cristina Nieto-Jimenez
- Experimental Therapeutics Unit, Hospital Clínico San Carlos, IdISSC, Fundación Jiménez Díaz, START, 28040 Madrid, Spain
| | - Iván Bravo
- Unidad nanoDrug, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain; (A.d.C.-B.); (I.B.); (C.R.)
- Departamento Química-Física, Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Consuelo Ripoll
- Unidad nanoDrug, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain; (A.d.C.-B.); (I.B.); (C.R.)
- Departamento Química-Física, Facultad de Farmacia de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | | | - Pawel Gancarski
- Cancerappy, Avda Ribera De Axpe, 28, 48950 Erandio, Spain; (E.P.-R.); (P.G.)
| | - Fernando Carrillo-Hermosilla
- Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain; (B.P.-C.); (F.C.-H.)
| | - Carlos Alonso-Moreno
- Unidad nanoDrug, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain; (A.d.C.-B.); (I.B.); (C.R.)
- Departamento Química Inorgánica, Orgánica y Bioquímica, Facultad de Farmacia de Albacete-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, 02008 Albacete, Spain
| | - Alberto Ocaña
- Experimental Therapeutics Unit, Hospital Clínico San Carlos, IdISSC, Fundación Jiménez Díaz, START, 28040 Madrid, Spain
| |
Collapse
|